Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
EP05.02 - Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy
-
+
EP05.02-016 - Aumolertinib after Adjuvant Chemotherapy/Radiotherapy in Stage pIIIA-N2 Non-Small-Cell Lung Cancer with EGFR Mutation
Presenter: Yu Zhang- Abstract
Loading... -
+
EP05.02-021 - An Updated Analysis of Toripalimab and Platinum-Doublet Chemotherapy as Neoadjuvant Therapy for Potentially Resectable NSCLC
Presenter: Yongchang Zhang- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
-
+
EP08.02-003 - Aumolertinib Plus Chemotherapy as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation andctDNA Cleared Analysis
Presenter: YanWei Li- Abstract
Loading... -
+
EP08.02-033 - Anlotinib in Elderly Patients With Advanced Non-squamous NSCLC Who Had Not Received Systemic Chemotherapy: A Single-Arm, Phase II Study
Presenter: da zhao- Abstract
Loading...